Fact CheckerSign in

NCT07806019Not yet recruitingPhase 4

Metformin in Parkinson's Disease: Safety and Efficacy

Clinical Efficacy and Safety Profile of Metformin in Parkinson's Disease

Source: ClinicalTrials.gov · Last updated 9 Sept 2026

Brief summary (registry, in English)

This study will evaluate whether metformin when it will be given to patients with Parkinson's disease along with standard therapy (levodopa carbidopa) will improve motor symptoms and decreases levels of alpha synuclein and MDA in patients with PD as compare to PD patients receiving only standard therapy (levodopa carbidopa)

Status (registry)
Not yet recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
70 (estimated)
First submitted
20 Aug 2026
Start date
28 Aug 2026
Primary completion date
1 Feb 2027
Lead sponsor
Jinnah Medical & Dental College
NCT number
NCT07806019

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 70
  • From 28 Aug 2026 to the primary completion date, 1 Feb 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Secondary Parkinsonism co-morbid (such as Diabetes mellitus, Cardio-vascular diseases, Senile tremors, Wilson's disease, Cancers etc.) Pregnant and lactating mothers Sensitivity to metformin Lactic acidosis History of alcohol use

Who the study is looking for

  • Male and female patients diagnosed with primary PD age 50-70 years receiving levodopa + carbidopa. Diagnosis will be made in accordance with movement disorder society clinical diagnostic criteria for Parkinson's disease

Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.